Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.33 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5781033 | 0.91 | ERN1 (0.40) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL1465179 | 0.83 | ERN1 (0.35) | ERN1PRKDCPIK3CAMTOR | |
| SCHEMBL1465182 | 0.83 | ERN1 (0.35) | ERN1PRKDCPIK3CAMTOR | |
| SCHEMBL29127157 | 0.81 | ERN1 (0.36) | ERN1PRKDCALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL29957378 | 0.79 | ERN1 (0.44) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL19330147 | 0.79 | ERN1 (0.46) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL9559282 | 0.79 | ERN1 (0.44) | ERN1PRKDCALDH1A1KDM4ETSHR | |
| SCHEMBL17594580 | 0.79 | AURKA (0.32) | ERN1SMN1; SMN2PIK3CAMTOR | |
| SCHEMBL17594581 | 0.79 | AURKA (0.32) | ERN1SMN1; SMN2PIK3CAMTOR | |
| SCHEMBL5784164 | 0.78 | ERN1 (0.46) | ERN1PRKDCALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669107-A | Antibacterial peptide and preparation method thereof | 上海医药工业研究院 | 2020-01-10 | — | — | CN | claimed |
| EP-2245132-B1 | ENCAPSULATED BENEFIT AGENT | UNILEVER PLC NO 41424 (GB) | 2017-10-18 | — | — | EP | claimed |
| CN-102015993-B | Encapsulated benefit agent | UNILEVER PLC | 2013-03-27 | — | — | CN | claimed |
| CN-102015993-A | Encapsulated benefit agent | UNILEVER PLC | 2011-04-13 | — | — | CN | claimed |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | disclosed |
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| EP-4146658-B1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PREC MEDICINE OPM (FR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4559525-A2 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | Morphic Therapeutic, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4045039-B1 | INHIBITING HUMAN INTEGRIN ALPHA4BETA7 | MORPHIC THERAPEUTIC INC (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025064535-A1 | TRICYCLIC SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090305-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| US-6784192-B2 | NA+ CHANNEL INHIBITORY ACTION IS USEFUL FOR THERAPY AND PREVENTION FOR EXAMPLE, ARRHYTHMIA, VARIOUS NEURALGIAS AND ANALGESIC | EISAI CO., LTD. (JP) | 2004-08-31 | — | — | US | disclosed |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-11-27 | — | — | US | disclosed |
| EP-1254904-A1 | NOVEL PIPERIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0178633-B1 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-4588733-A | 2-phenylpyrano[2,3-b]pyridines and their use in inhibiting viruses | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0178633-A2 | 2-phenylpyrano[2,3-b]pyridines | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | ERN1 487/4885PRKDC 72/4885ALDH1A1 2875/4885 |
| US-12221416-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | ERN1 3601/4885PRKDC 3913/4885ALDH1A1 1396/4885 |
| US-20030220368-A1 | Novel piperidine compouds and drugs containing the same | TRPV1, CACNA1D, KCND2 | ERN1 3488/4885PRKDC 3767/4885ALDH1A1 408/4885 |
| US-12637418-B2 | Heterocyclic compounds as antagonist of NMDA | GRIN1, GRIN3A, GRIN2A | ERN1 3833/4885PRKDC 3193/4885ALDH1A1 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.